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Abstract
Objective—To evaluate the association between HIV infection and sexual maturation, and 
mediation of this association by HIV effects on growth.
Design—Pooled data were analyzed from two longitudinal cohort studies, the IMPAACT 
P219/219C Study (1993–2007) and the PHACS Adolescent Master Protocol (2007–2015), 
including perinatally HIV-infected (PHIV) and HIV-exposed uninfected (PHEU) youth.
Methods—We evaluated age at sexual maturity among 2539 PHIV and PHEU adolescents based 
on annual physician-assessed pubertal staging measures. Interval-censored regression models were 
used to evaluate associations of HIV infection with age at maturity. Mediation analyses accounting 
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for height and body mass index (BMI) Z-scores at specific ages were used to estimate direct and 
indirect effects of HIV infection on age at sexual maturity.
Results—Mean ages at sexual maturity for PHIV girls (n=1032) were 15.5 years for both female 
breast and pubic hair and 15.9 and 15.8 years for PHIV boys (n=1054) for genitalia and pubic hair, 
respectively. PHIV youth matured approximately 6 months later on average than PHEU (n=221 
girls, 232 boys), and this difference persisted after adjustment for race/ethnicity and birth cohort. 
BMI and height Z-scores mediated the association between HIV infection and later maturation in 
girls, accounting for up to 74% of the total HIV effect. Only height Z-scores mediated the effect of 
HIV on male age at maturity, accounting for up to 98% of the HIV effect.
Conclusion—PHIV youth attain sexual maturity later on average than PHEU youth. Much of 
this difference may be attributable to deficient growth, suggesting directions for future 
interventions.
Keywords
puberty; growth; HIV; sexual maturity; perinatal; mediation; interval-censoring
Introduction
The transition from a pre-pubertal state to sexual maturity occurs through a complex series 
of biological transformations known as puberty. This transition plays a critical role in child 
development, and pubertal timing has significant social and clinical implications [1]. Over 
the past 15 years, a trend towards earlier onset of puberty has been documented, particularly 
in girls [2]. This trend has been accompanied by increased rates of childhood obesity and 
declining physical activity levels, especially in more developed countries [3].
Studies in perinatally HIV-infected (PHIV) children have shown delayed pubertal onset [4–
7] and some evidence of delays in attaining sexual maturity [7] compared to HIV-uninfected 
peers, with greater delay among those with greater disease severity [6,7]. In particular, we 
previously reported that the adjusted mean age at pubertal onset was delayed by 6 months in 
PHIV as compared to perinatally HIV-exposed uninfected (PHEU) youth, and by 4 to 13 
additional months in PHIV youth with lower CD4 T-lymphocyte percentages (<15%) or 
higher HIV viral loads (above 10,000 copies/mL) [6]. The biological pathways through 
which perinatal HIV infection affects the timing of pubertal onset and sexual maturity are 
mostly unknown, limiting effective interventions for infected youth. As pubertal delay is 
known to correlate with poor growth in other populations, we hypothesized that growth 
deficits during late childhood may mediate an association between perinatal HIV infection 
and delayed sexual maturation [7–14].
Using data from two longitudinal cohort studies of children born to HIV-infected mothers, 
we evaluated the effect of perinatal HIV infection on the age at sexual maturity and 
employed novel approaches within a mediation analysis framework to investigate the 
proportion of this effect that might be explained by deficient growth.
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Methods
Study population
This study included youth from two US-based longitudinal cohort studies of children born to 
HIV-infected mothers, the 219/219C study of the International Maternal Pediatric 
Adolescent AIDS Clinical Trials (IMPAACT) Network and the Adolescent Master Protocol 
(AMP) study of the Pediatric HIV/AIDS Cohort Study (PHACS) Network. The 219/219C 
study enrolled PHIV and PHEU children at more than 80 sites in the US between 1993–
2007 and was designed to evaluate long-term effects of HIV infection and perinatal HIV 
exposure [6]. AMP was established in 2007 and is a smaller, ongoing cohort study of PHIV 
and PHEU children who were 7–16 years old at entry [12]. Approximately 70% of AMP 
youth previously participated in the 219/219C study. Both studies were approved by 
Institutional Review Boards at Harvard T.H. Chan School of Public Health and at all clinical 
research sites, and written informed consent was obtained from each parent or legal 
guardian, with assent from children as appropriate.
Children had scheduled visits every 3 months in the 219/219C study and every 6 (until 2010) 
or 12 months (2010 and later) in the AMP study. Medical histories and health status were 
ascertained at each study visit through chart reviews, physical examinations, and laboratory 
evaluations. Race and ethnicity were self-reported at entry and categorized as white non-
Hispanic, black non-Hispanic, Hispanic, or ‘other’. For the current analysis, we excluded 
children without a study visit after the age of 7 years and children who were at later stages 
of sexual development (Tanner stages 3 to 5) at their first study visit, yielding a final study 
population of 2539 children (1253 girls, 1286 boys). Among these, we considered study 
visits occurring after 7 years through 20 years of age.
Growth and sexual maturity assessments
Height and weight measurements and pubertal staging assessments were recorded at each 
study visit. Pubertal staging was assessed by visual inspection by study clinicians of breast 
development and pubic hair in girls and genitalia and pubic hair in boys, according to the 
criteria of Tanner and Whitehouse, with stages ranging from 1 (pre-pubertal) to 5 (mature) 
[15].
Statistical methods
For each participant, the date of the first pubertal assessment at age 7 years or older was 
used to define the start of follow-up. Measurements of height and weight were used to 
calculate age- and sex-adjusted Z-scores for height and body mass index (BMI) according to 
growth standards of the Centers for Disease Control and Prevention (CDC) [16].
Interval-censored approaches for survival outcomes were used to account for the fact that 
sexual maturity may occur between study visits rather than on a specific study visit date; this 
approach also allowed for right-censored outcomes, to reflect situations in which sexual 
maturity had not yet occurred by the last study visit. Interval-censored models were fit using 
accelerated failure time (AFT) models under a normal distribution assumption for age at 
sexual maturity [6, 12, 17]. We first estimated the mean age at sexual maturity separately for 
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each pubertal marker, by HIV infection status, race/ethnicity, and birth cohort. We also 
evaluated the mean age [95% confidence interval (CI)] for each of the four puberty markers 
by HIV infection status adjusted for race/ethnicity and birth cohort. This final model was 
replicated in two sensitivity analyses to assess whether results were influenced by the 
unbalanced distribution of birth years between HIV-infected and uninfected children. First, 
we restricted the sample to those children born after 1993, thus excluding those categories 
with a limited number of PHEU children. Next, we repeated the analysis by randomly 
selecting a sample of children born after 1993 matched for birth cohort. Adjusted mean ages 
at menarche were also calculated by HIV status among the subset of girls with this 
information available; an AFT model with an assumed normal distribution was used 
accounting for right censoring for girls not reaching menarche by their latest assessment.
Mediation analysis was conducted to partition the total effect of HIV infection at birth on the 
age at sexual maturity into a direct effect of HIV infection, not acting through height and 
BMI z-scores, and an indirect effect acting through height and BMI Z-scores (mediators). 
We hypothesized that some proportion of the effect of HIV infection on sexual maturity 
might be explained by effects of deficient height experienced by PHIV children. Mediation 
analysis in this context requires modeling age at maturity as a function of HIV infection, 
repeating this model further adjusting for the mediator(s), and separately modeling the 
mediators as a function of HIV infection [18,19]. In this study, we applied an extension of 
the method to jointly evaluate the effect of two mediators (height and BMI Z-scores) [20]. 
Coefficients corresponding to the HIV infection effects without and with adjustment for the 
mediators were used to estimate, respectively, the total effect and direct effect of HIV 
infection, using interval-censored methods as previously described. The indirect effects, 
acting through differences in growth, were calculated by fitting separate models for the 
height and BMI Z-score mediators and multiplying the HIV coefficients from these models 
with the HIV coefficient from the mediator-adjusted maturity model [18,21,22]. We present 
results in terms of proportion mediated, calculated for each mediator as the ratio between the 
indirect and the total effect. Because our mediators were continuous, linear models were 
utilized to model the HIV-mediator relationships for height and BMI Z-scores. All statistical 
models were further adjusted for race/ethnicity and birth cohort. Possible interactions of the 
mediators with each other and with HIV were also explored by extending the multiple 
mediators approach proposed by Vanderweele and Vansteelandt [20]. However, no evidence 
of such interactions were detected, and all presented results omit interaction terms.
Because height and BMI change over time, their contribution in the causal pathway from 
HIV infection to sexual maturity might vary by age. Our repeated measures of height and 
BMI allowed exploration of how the percent mediated effect varied at different time points 
in adolescence. For each sexual maturity marker, mediation analysis was replicated based on 
height and BMI Z-scores at four different ages (each in a separate model, as illustrated in 
Figure 1): at the first study visit and at ages 10, 11, and 12 years. To allow comparison 
between the four scenarios, the mediation models were restricted to ~500 children of each 
sex who had a first study visit before age 10 years, at least one visit per year between 10–12 
years, and experienced sexual maturity after 12 years. When multiple visits per year were 
available, the visit closest to the subject’s birthday was used. All statistical analyses were 
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performed with the R package survreg. Statistical tests were two-tailed and p-values <0.05 
were considered statistically significant.
Results
Characteristics of the study population at baseline (first visit at 7 years or older) are 
presented by HIV infection status and sex in Table 1. The 453 PHEU children were on 
average younger and had greater height and BMI Z-scores than the 2086 PHIV youth. The 
distribution of sex and race were similar between PHIV and PHEU youth, with high 
percentages of black non-Hispanic and Hispanic youth in both groups.
During a median follow-up of 4 years, 338 boys (27%) and 385 girls (31%) achieved sexual 
maturity according to at least one pubertal marker. Mean ages at sexual maturity were 15.5 
years (95% CI: 14.5, 16.5) and 15.5 years (14.4, 16.6) for breast and pubic hair among PHIV 
girls, and 15.9 years for genitalia (14.8, 17.1) and 15.8 years for pubic hair (14.7, 16.9) 
among PHIV boys (Table 2).
Compared to PHEU youth, PHIV children showed consistently later attainment of sexual 
maturity by ~6 months for all puberty indicators (Table 2). These differences attained 
statistical significance only for breast maturity in females, but exhibited consistent trends for 
other maturity indicators. In the overall sample, race was significantly associated with age at 
sexual maturity only among females, with black non-Hispanic girls experiencing maturity 5 
months earlier on average than white non-Hispanic girls (Table 2). Among black non-
Hispanic youth, the estimated mean ages at sexual maturity among PHEU youth were 14.2 
(13.5, 14.9) and 14.4 (13.7, 15.1) years for breast and pubic hair among girls, respectively, 
and 15.1 years (14.3, 15.9) for both markers for boys. A temporal trend was also 
documented, with a significant decrease in mean age for younger birth cohorts (i.e., born 
more recently) for all maturity markers. This trend remained significant after adjusting for 
HIV infection status and race/ethnicity. After adjustment for race/ethnicity and birth cohort, 
the mean age at sexual maturity was consistently older for PHIV than for PHEU youth, but 
significant differences were no longer observed (Table 2). Our two sensitivity analyses 
(excluding children born before 1993 and matching by birth cohort) showed negligible 
differences from our original findings, suggesting minimal influence of the imbalance in 
birth years between HIV-infected and uninfected children (Supplementary Tables S1 and 
S2). The mean age at menarche in a subset of 390 girls with available information was 12.5 
years for PHIV girls and 12.0 years for PHEU girls, reflecting a delay of 5 months in both 
the unadjusted (4.9 months; 95% CI: 1.3, 8.5) and adjusted models (5.2 months; 95% CI: 
1.4, 9.1).
Table 3 shows the effect of perinatal HIV infection status on growth measures in a 
subsample of the study population with annual visits between ages 9–12 years, stratified by 
sex. After adjusting for race/ethnicity and birth cohort, PHIV youth had significantly lower 
height Z-scores at all ages evaluated, with the largest difference at age 11 for girls and age 
12 for boys. While BMI Z-scores were also lower among PHIV than PHEU youth at all 
ages, differences were not significant.
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Results from the mediation models are presented in Figure 2. Growth as reflected by height 
and BMI z-scores mediated a large proportion of the total effect of HIV infection on age at 
sexual maturity for all pubertal markers, with considerable differences between boys and 
girls. Among females, both BMI and height Z-scores played a substantial role, with the 
strongest association at age 11: 74% of total effect was mediated by the two growth 
measures for both breast and pubic hair maturity. Among males, the proportion mediated by 
growth progressively increased with age, explaining up to 53% of the lag in genitalia 
maturation and 98% of the lag in pubic hair maturation at age 12 years. However, in contrast 
to girls, indirect effects were entirely attributable to height Z-score, with no evidence that 
BMI Z-score mediated the effect of HIV infection on timing of sexual maturity.
Discussion
This study is one of the first to estimate age at sexual maturity among youth with perinatal 
HIV infection and to evaluate differences between infected and uninfected youth within the 
context of a large prospectively-followed cohort. We observed a delay in the age at sexual 
maturity among PHIV youth compared to PHEU youth. Moreover, we found that this effect 
was partly mediated by deficient height experienced by PHIV children. The impact of 
growth differed by sex, with both lower height and BMI among girls contributing to later 
age at maturity while only lower height appeared to mediate effects of HIV on timing of 
sexual maturity among boys. The contribution of growth as a mediator of the effect of HIV 
on sexual maturity varied with age, with the strongest contribution at age 11 for girls and age 
12 for boys. This finding is not unexpected given the typically earlier pubertal onset of girls 
as compared to boys [6].
While previous studies addressed differences between PHIV and PHEU children in timing 
of pubertal onset [4–7], few studies have evaluated sexual maturity among PHIV youth [7]. 
The shift in mean age at maturity of approximately 6 months in PHIV as compared to PHEU 
adolescents is similar to that previously observed for age at pubertal onset [6], suggesting 
that once pubertal onset has begun the pace of pubertal progression remains similar in PHIV 
and PHEU youth.
Clinical effects of a shift of 6 months in the age at sexual maturity are anticipated to be 
subtle, and may not reflect “clinical delay” for most PHIV youth, but may nevertheless 
translate to a higher than expected percentage of PHIV youth with clinically delayed 
maturity. Based on age at Tanner stage 5 more than 2 standard deviations above sex- and 
race-specific means (from Susman et al [23]), 9.9% of PHIV boys and 10.7% of PHIV girls 
met the criteria for clinically delayed sexual maturation, as compared to an expected 2.5% in 
the general US population. In addition, there may be other public health implications of 
alterations in timing of sexual maturity, including reduced self-esteem and decreased bone 
mineral density. Previous research has focused predominantly on associations of early 
puberty on adverse health outcomes [1, 24], but recent findings have indicated associations 
of delayed puberty with increased risk of specific cancers. For example, Lope and colleagues 
recently reported a 6% increase in risk of prostate cancer for each 1-year delay in pubertal 
onset in boys [25].
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A recent African study of PHIV youth reported mean ages of 16.1 and 16.5 years for breast 
and pubic hair maturity in girls and 16.9 and 16.8 years for genitalia and pubic hair maturity 
in boys [7]. These later mean ages at maturity than those we observed may be partially 
explained by greater height and weight deficits in HIV-infected children in Africa relative to 
those of the US [26, 27]. Consistent with our findings of strong effects of growth on pubertal 
maturation, this African study found that lower height was associated with additional 
pubertal delays among HIV-infected boys and girls, and also observed effects of BMI on 
pubertal maturation only in girls [7, 14]. Other diseases known to affect growth in children, 
such as type 1 diabetes and cystic fibrosis, have also been shown to affect sexual maturation 
[28, 29].
Growth delays in HIV-infected children, including those receiving combination ART, are 
common and not typically associated with growth hormone deficiency. However, low IGF-I 
levels may be present, possibly mediated by chronic inflammation causing increased 
production of cytokines or by under-nutrition, either of which may lead to a state of growth 
hormone (GH) resistance [30, 31]. Evidence also exists for concomitant GH and IGF-I 
resistance in association with HIV infection [32, 33]. In the present study, height had 
differential effects on genitalia and pubic hair maturation in boys; height explained about 
half of the HIV effect on genital maturation, but almost 100% of the effect on pubic hair. 
The pulsatile secretion of gonadotropin-releasing hormone (GnRH) triggers pituitary 
secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which, in 
boys, drive testicular growth and spermatogenesis, respectively [34, 35]. In contrast, the start 
of pubic hair maturation is linked to adrenal maturation (adrenarche), the exact hormonal 
controller of which is unknown. Thus, it is not entirely unexpected that the role linear 
growth plays in affecting subsequent maturity may vary between these two pathways.
Our analysis represents a novel approach for evaluating the contributions of both HIV 
infection and growth on timing of sexual maturity. Using recently developed mediation 
analysis frameworks, we were able to evaluate multiple mediators (height and BMI) and 
their interactions on age at maturity [18,20]. Mediation analysis approaches for survival 
outcomes have only been recently developed and, to our knowledge, have not specifically 
been applied to interval-censored outcomes [19]. However, the framework of AFT models 
allows parametric models to be specified for the interval-censored outcomes of interest, and 
identification of indirect and direct effects of the primary exposure of interest (in this case, 
perinatal HIV infection) follows directly from previous assertions [19].
The large size of our cohort, longitudinal follow-up over almost 4 years, inclusion of an 
uninfected comparison group from a similar racial and socioeconomic background, and 
annual physician-assessed evaluations of pubertal staging are key strengths of our study; 
however, we recognize that our study has some limitations. Our observational cohort of 
perinatally infected youth represents a survivor cohort, particularly for youth born in the 
earliest years when effective antiretroviral therapy was not available. In addition, youth 
without HIV infection tended to be born in later years as a result of shifts in the HIV 
epidemic and improved management of HIV-infected pregnant women; thus, distinguishing 
trends over time within this subgroup is restricted to later birth cohorts. In addition, due to 
the generally younger age at study entry for PHEU youth, a much smaller percentage had 
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been followed until an age at which sexual maturity would be expected, despite a similar 
duration of overall follow-up from study entry. Finally, the effect of HIV infection on timing 
of sexual maturity via its effect on growth may also be partially attributable to the previously 
demonstrated association of HIV with later pubertal onset, which in turn affects subsequent 
growth. Our approach evaluated the overall association between HIV infection and growth 
through multiple pathways, including alterations in the timing of pubertal onset.
To consider the role of growth measures at different ages while limiting the effects of 
selection bias, we restricted our mediation analysis to a smaller subset of youth with 
consistent annual follow-up measures, which reduced our power for detecting statistically 
significant associations. As such, results from the mediation analyses models should be 
interpreted with caution and need to be replicated in larger cohorts. Like all observational 
cohorts, there is also the potential for unmeasured confounding, but our findings were 
relatively robust after adjustment for race/ethnicity and birth cohort. However, the presence 
of unmeasured confounders, especially of the mediator-outcome associations, cannot be 
excluded, and may limit the causal interpretation of our results [36]. The limited number of 
participants achieving maturity by the end of follow-up may also limit the interpretation of 
our results. However, these two prospective cohorts are characterized by a high retention 
rate, with less than 5% of study participants lost to follow-up each year [37]. Censoring was 
primarily due to study closure or administrative censoring and thus was unlikely to bias 
analysis results. Another possible limitation is the imbalance in age at baseline between 
PHIV and PHEU children, which might increase the risk of selection bias due to exclusion 
of a higher proportion of PHIV children who were sexually mature at baseline.
Finally, given the relatively limited number of youth who attained maturity during the course 
of the study, we were unable to address the impact of specific ART regimens or markers of 
immune status on timing of sexual maturity. The benefits of combination ARV regimens 
have led to improvements in growth, at least in more developed countries, which may 
translate into reductions in previously observed delays in pubertal maturation. Future studies 
to evaluate the relationships between age of combination ARV initiation (and specific ARV 
regimens), height and BMI, and sexual maturation are warranted as more perinatally 
infected children transition to young adulthood.
In conclusion, PHIV youth experience delays in pubertal maturation that may have adverse 
long-term consequences, including reduced self-esteem and decreased bone mineral density, 
along with possible increased risks of some cancers [1,24,25,35]. The deficient growth 
experienced by PHIV children was found to be an important contributor to this negative 
effect. Effects mediated through growth differed by growth measures (BMI vs. height) and 
sex and between markers of maturity for boys. The role of growth in altering pubertal 
development of PHIV children indicates a potential for interventions (including early ART) 
that should ideally be initiated prior to the adolescent growth spurt.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Illustration of mediation analysis of the role of height and BMI Z-scores in explaining the 
effect of perinatal HIV infection on the age at sexual maturity. The four scenarios were 
investigated in four separated statistical models by selecting different time points for the 
intermediate variables. For simplicity, the figure does not include potential confounders.
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Figure 2. 
Proportions of the total effect of perinatal HIV infection on the age at sexual maturity 
mediated by height Z-scores (dark grey) and BMI Z-scores (light grey) (“indirect effect”), 
according to four indicators of sexual maturity. Results were obtained by fitting mediation 
analysis models on ~500 children of each sex (breast: n=491; female pubic hair: n=487; 
genitalia: n=522; male pubic hair: n=526) with assessments at all 4 time points, 
corresponding to the four panels of Figure 1. No significant results were observed in this 
analysis.
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Table 1
Characteristics of the IMPAACT 219/219C and PHACS AMP study population, by HIV status, at the first 
study visit at age 7 years or older (n=2539)
Characteristics
Perinatally HIV-exposed uninfected (PHEU) 
(n=453)
Perinatally HIV- infected (PHIV)(n=2086)
Boys (n=232) Girls (n=221) Boys (n=1054) Girls (n=1032)
Age at baselinea (years), median (IQR) 7.6 (7.2–8.5) 7.5 (7.2–8.1) 8.0 (7.4–9.9) 7.9 (7.3–9.5)
Study
 AMP and 219/219C 45 (19%) 56 (25%) 139 (13%) 157 (15%)
 219/219C 133 (57%) 132 (60%) 872 (83%) 846 (82%)
 AMP only 54 (24%) 33 (15%) 43 (4%) 29 (3%)
Birth cohort
 Before 1990 0 (0%) 0 (0%) 272 (21%) 228 (22%)
 1990–1992 2 (9%) 19 (9%) 322 (27%) 332 (32%)
 1993–1996 63 (27%) 87 (39%) 325 (30%) 319 (31%)
 1997 or later 147 (63%) 115 (52%) 135 (13%) 153 (15%)
Race/ethnicity
 White non-Hispanic 26 (11%) 27 (12%) 131 (12%) 135 (13%)
 Black non-Hispanic 115 (50%) 115 (52%) 599 (57%) 598 (58%)
 Hispanic 89 (38%) 73 (33%) 305 (29%) 276 (27%)
 Other/unknownb 2 (1%) 6 (3%) 19 (2%) 23 (2%)
Pubertal onset at baselinec 29 (6%) 48 (11%) 138 (7%) 198 (9%)
Height Z-score at baseline, mean (SD) 0.26 (1.08) 0.13 (1.07) −0.71 (1.23) −0.58 (1.16)
BMI Z-score at baseline, mean (SD) 0.83 (1.25) 0.68 (1.21) 0.31 (1.07) 0.25 (1.01)
BMI=body mass index; IQR=interquartile range; SD=standard deviation
a
Baseline was defined as first pubertal assessment at age 7 years or older
bOther race or multiracial:1,1,9,5; Unknown: 1,5,12,18.
c
Pubertal onset defined as achieving either stage 2 breast or stage 2 pubic hair development for girls, and as either stage 2 genitalia or stage 2 pubic 
hair development in boys
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Table 3
Adjusted differences in height and BMI Z-scores at different ages between perinatally HIV-infected youth as 
compared to perinatally HIV-exposed but uninfected youth, within the subset having annual follow-up at ages 
10 through 12 years
Age (years)
Height Z-score BMI Z-score
Estimated Difference 95% CI for difference Estimated Difference 95% CI for difference
Girls (n=491)a
 Baseline −0.66 (−1.06, −0.27) −0.12 (−0.50, 0.27)
 Age 10 −0.62 (−1.04, −0.20) −0.20 (−0.58, 0.17)
 Age 11 −0.65 (−1.14, −0.16) −0.25 (−0.65, 0.14)
 Age 12 −0.56 (−0.99, −0.13) −0.13 (−0.52, 0.26)
Boys (n=526)b
 Baseline −0.51 (−0.91, −0.10) −0.02 (−0.39, 0.34)
 Age 10 −0.60 (−0.98, −0.22) −0.10 (−0.48, 0.28)
 Age 11 −0.62 (−0.99, −0.25) −0.09 (−0.61, 0.43)
 Age 12 −0.75 (−1.15, −0.39) −0.19 (−0.61, 0.22)
CI=confidence interval; BMI=body mass index (kg/m2). Estimates are adjusted for race/ethnicity and birth cohort.
a32 PHEU, 459 PHIV
b36 PHEU, 490 PHIV
AIDS. Author manuscript; available in PMC 2018 June 01.
